When deciding which postmenopausal women under 65 to screen, the USPSTF recommended that clinicians first take stock of risk ...

Diagnosis. Osteoporosis, persistent after 12 years of hormone replacement therapy, and celiac disease. Management. The patient was initially treated for bone loss with postmenopausal hormone ...

Raloxifene is FDA approved for the prevention and treatment of postmenopausal osteoporosis and for the prevention of invasive breast cancer in postmenopausal women at high risk for breast cancer.

In a final recommendation statement, the U.S. Preventive Services Task Force said that all women aged 65 years and older ...

All women 65 and older should continue to be screened for osteoporosis, the nation’s leading preventive health panel ...

Researchers at Hospital for Special Surgery (HSS) have pinpointed a cellular target that could enhance the way osteoporosis ...

Long-term bisphosphonate treatment of postmenopausal osteoporosis is associated with reduction of bone turnover and might, therefore, have deleterious adverse effects on the repair of microdamage ...

All treatments for 2 yr BMD improved more ... group had reduction in UcOC without change in OC 54 94 postmenopausal women with osteoporosis (84 controls, 10 treated) Menaquinone 45 mg/day ...